Market Intelligence, Clinical Progress, and High-Purity Reagents for Immuno-Oncology and Inflammatory Disease Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for ARG1 drug discovery.
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | ARG1 Recombinant Protein (WT & Catalytic Mutant Panel) High purity (>95%), Endotoxin <1 EU/µg. Sequence Verified. Expressed in HEK293. |
View ARG1 Products |
| Isoform Control | ARG2 (Kidney-type) Recombinant Protein For selectivity counter-screening. Sequence Verified. |
View ARG2 Products |
| Gene Delivery | ARG1 Promise-ORF / Lentivirus Full-length ORF for stable cell line construction and overexpression models. |
View ARG1 Products |
| Detection Ab | Anti-ARG1 Recombinant Antibody (High Affinity Clone) For IHC, Western Blot, Flow cytometry detection. |
View ARG1 Products |
| Validator | ARG1 siRNA Set For knockdown verification in cell-based assays. |
View ARG1 Products |
| Related Target: ARG2 | Arginase-2 (mitochondrial isoform) for selectivity assays. | View ARG2 Products |
| Related Target: IDO1 | Indoleamine 2,3-dioxygenase 1; synergistic metabolic checkpoint in TME. | View IDO1 Products |
| Related Target: NOS2 | Nitric oxide synthase 2 (iNOS); competing arginine-consuming enzyme. | View NOS2 Products |
| Related Target: ASS1 | Argininosuccinate synthase 1; arginine synthesis pathway node; synthetic lethality biomarker. | View ASS1 Products |
Critical Assay Challenges & The TarMart Advantage
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Isoform Selectivity (ARG1 vs ARG2) | Matched pair of ARG1 and ARG2 proteins with >95% purity for side-by-side SPR or activity inhibition assays. |
| Cell-based Target Engagement & Intracellular Validation | ARG1 Lentivirus for stable overexpression in myeloid cell models; siRNA for loss-of-function validation. |
| Enzyme Activity Standardization & Assay Reproducibility | High-purity ARG1 (>95%, <1 EU/µg) with preserved native folding, suitable for urea detection assays. |
| Biochemical Assay False Positives | Catalytic-dead mutant panel included as negative controls; validated siRNA for specificity controls. |
| Cross-species Preclinical Evaluation | Human, Mouse, Cynomolgus ARG1 recombinant proteins with endotoxin control (<1 EU/µg). |
| Lack of Validated Pathway Controls | Sequence-verified Benchmark Antibodies and validated siRNA for robust specificity checks. |
Global Clinical Landscape & Future Outlook
The race for ARG1-targeted therapeutics is intensifying, driven by the critical role of Arginase-1 in immune evasion within the tumor microenvironment (TME). Myeloid-derived suppressor cells (MDSCs) and tumor-associated macrophages (TAMs) overexpress ARG1 to deplete L-arginine, thereby starving T-cells and suppressing the anti-tumor immune response. First-generation small molecule inhibitors faced efficacy hurdles; the current R&D pivot emphasizes biomarker-driven patient stratification and combination regimens with checkpoint inhibitors (e.g., PD-1/PD-L1 blockade). With major players focusing on small molecule inhibitors, the clinical landscape is shifting toward rational combinations to improve response rates. The next wave of R&D targets highly selective TME-specific inhibition to avoid systemic toxicity and improve therapeutic windows. Key companies include Incyte (INCB001158), Calithera, and Arcus, while Aeglea BioTherapeutics pursues recombinant enzyme therapy (pegzilarginase) for ARG1 deficiency and metabolic cancers.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Inhibitor | Calithera Biosciences, Incyte, Arcus | Solid Tumors (NSCLC, RCC, Colorectal, Myeloid Leukemia) | Enzymatic IC50 Screening (Need High-Purity WT & Mutant ARG1) |
| Combination Immunotherapy | Academic Consortia, Big Pharma | Advanced Solid Tumors | Cell-based MDSC Suppression Assay (Need lentivirus/siRNA for target modulation); TME pathway profiling |
| Biomarker Diagnostics | Companion Diagnostic Developers | Immuno-oncology screening | IHC-grade Detection Antibodies (Need recombinant positive controls) |
| Recombinant Enzyme Therapy | Aeglea BioTherapeutics | ARG1 Deficiency / Metabolic Cancers | PK/PD Assays (Need sequence-verified anti-ARG1 benchmark antibodies) |
| RNAi / ASO | Preclinical Biotech | Solid Tumors | Knockdown Validation (Need ARG1 siRNA and target-specific lentivirus) |
| Arginine Depletion Therapy (Adjunct) | Polaris Group (ADI-PEG 20) | Hepatocellular Carcinoma, Melanoma | Pathway Protein Panel (Need ASS1, ARG1, ARG2 for biomarker profiling) |
Key Mutations and Scientific Insights
Arginase-1 mutations have been identified that significantly reduce enzymatic activity. Notable examples include a mutation (rs28941474) resulting in 12% of wild-type activity, a mutation (rs1326930389) resulting in 5.2% activity, and another mutation leading to 9.3% activity (UniProt P05089). These variants are valuable tools for studying structure-activity relationships and for developing negative controls in enzymatic assays.
Live ARG1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly: